United States

Press Release Archive

08/29/2016
Seqirus receives FDA approval for AFLURIA® QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older
Seqirus announced today that the US Food and Drug Administration (FDA) has approved AFLURIA® QUADRIVALENT (Influenza Vaccine) for use in persons 18 years of age and older. AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Both AFLURIA QUADRIVALENT and AFLURIA® (Influenza Vaccine), are available in the US for the 2016-2017 influenza season. More.

08/24/2016
Seqirus to highlight new data in seasonal influenza prevention at Options IX for the Control of Influenza conference
Seqirus announced today that seven poster presentations reporting results of the company’s research and development in seasonal influenza prevention and control have been accepted at the Options IX for the Control of Influenza conference (Options IX) in Chicago, 24-28 August 2016. More.

08/24/2016
Seqirus Presents Integrated Analyses for Trivalent Adjuvanted Seasonal Influenza Vaccine for Young Children
Seqirus today announced results of two data integrated analyses from six randomized clinical trials evaluating the safety and immunogenicity of its trivalent MF59-adjuvanted seasonal influenza vaccine in children aged six months to less than six years. 1,2 More.

08/17/2016
Seqirus now shipping its complete portfolio of seasonal influenza vaccines to US market for the 2016-2017 season
Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine. More.

08/16/2016
Seqirus announces shipment of FLUADTM (Influenza Vaccine, Adjuvanted) in the US for 2016-2017 flu season
Seqirus has begun shipping FLUADTM (Influenza Vaccine, Adjuvanted) for the 2016-2017 flu season since gaining approval from the Food and Drug Administration (FDA) late November last year. FLUAD is the first and only adjuvanted seasonal influenza vaccine approved in the United States, and was specifically developed to help protect adults aged 65 and older from the flu. More.

05/23/2016
Seqirus receives FDA approval for FLUCELVAX QUADRIVALENT™ (Influenza Vaccine) for people four years of age and older
“We are pleased to offer FLUCELVAX QUADRIVALENT, which is produced at our full-scale cell culture influenza vaccine manufacturing facility in North Carolina, to our valued customers during the 2016-2017 flu season.” More.

05/12/2016
Seqirus Honored with National Award for Outstanding Efforts in Influenza Prevention
Seqirus announced today that the National Adult and Influenza Immunization Summit (NAIIS) awarded the organization with the 2016 Immunization Excellence Award for best Corporate Campaign. The accolade recognizes Seqirus’ creative and collaborative efforts to improve vaccination awareness and rates during the 2015-16 influenza season. The award was presented yesterday during the NAIIS Summit in Atlanta, Georgia. More.

11/25/2015
Seqirus receives FDA approval for FLUAD™ (Influenza Vaccine, Adjuvanted) for adults aged 65 years and older
Seqirus announced today that the US Food and Drug Administration (FDA) has approved Fluad™ (Influenza Vaccine, Adjuvanted) to help protect those aged 65 years and older against seasonal influenza. Fluad is the first adjuvanted seasonal influenza vaccine approved in the United States; it was specifically developed for the adult population aged 65 and older.1 More.

11/09/2015
CSL brands world’s no. 2 influenza vaccine provider as Seqirus
Global biotherapeutics leader CSL Limited announced that its influenza vaccines business will begin operating under the brand Seqirus effective today, following the merger of the recently-acquired Novartis influenza business and its existing vaccines and pharmaceutical business bioCSL. More.

10/29/2015
CSL convenes industry and government leaders to discuss improving influenza vaccination rates and pandemic preparedness
Today, at Pennsylvania Bio’s Life Sciences Future conference, CSL Chief Executive Officer Paul Perreault convened a panel of industry, advocacy and government leaders to discuss opportunities to make improvements in U.S. influenza (flu) vaccination rates and pandemic flu preparedness. More.

07/31/2015
Update on Novartis influenza vaccines acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has secured the necessary approvals required to proceed with the acquisition of the influenza vaccines business of Novartis and that it is working with Novartis to bring forward the close date for the transaction. The Company also said the new CSL subsidiary resulting from the acquisition will be called Seqirus. More.

07/13/2015
bioCSL Inc. Begins Shipping AFLURIA for the 2015-2016 US Seasonal Influenza Campaign
bioCSL Inc. announced today it has begun shipping AFLURIA, Influenza Vaccine in advance of the 2015-2016 influenza season. In support of improving seasonal influenza vaccination rates to protect public health, bioCSL will deliver more than 18 million doses of AFLURIA to the US market, a 20 percent increase over last year. More.

06/17/2015
BioCryst Licenses Worldwide Rights to Commercialize RAPIVAB® Influenza Treatment to CSL Limited
BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) and CSL Limited (ASX:CSL) (USOTC:CSLLY) - BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, announced today that it has licensed RAPIVAB (peramivir injection) for the treatment of influenza to CSL Limited, a global biopharmaceutical company. More.

11/25/2014
New PSA Reminds College Students That Vaccination is the Best Form of Protection Against Dangerous Flu Virus
Although the Centers for Disease Control and Prevention (CDC) recommends that everyone six months of age and older get a flu vaccine every season,1 college-aged adults have documented vaccination rates of just 8 to 30 percent.2,3,4,5 To help educate this vulnerable group and encourage vaccination, a collaboration of flu stakeholders launched a new Public Service Announcement (PSA) to broach a serious topic with college-aged adults. bioCSL Inc. has partnered on the PSA with Families Fighting Flu and Alana's Foundation, two nonprofit organizations of families who have lost children to, or whose children have suffered serious health complications due to the flu, that work to increase vaccination rates. More.

10/27/2014
CSL to acquire Novartis’ influenza vaccine business
CSL Limited has today announced an agreement to acquire Novartis’ global influenza vaccine business for US$275 million, which will be combined with CSL’s existing vaccines and pharmaceutical subsidiary, bioCSL. More.

10/20/2014
bioCSL Inc. Completes 2014‐15 Flu Season Shipment of AFLURIA®
bioCSL Inc. announced today that it has completed shipment of 16.2 million doses of AFLURIA® (Influenza Vaccine) for the 2014-2015 season and is now sold out. The Company’s distribution of 16.2 million doses represents a 45 percent increase in doses compared with the 2013-14 flu season for AFLURIA®. More.

08/19/2014
FDA Approves Use of AFLURIA® Influenza Vaccine with PharmaJet’s Needle-Free Injector
PharmaJet® Inc., the developer of a needle-free injection technology to administer medications and vaccines to patients, and bioCSL Inc., the maker of AFLURIA® (Influenza Vaccine) today announced the U.S. Food and Drug Administration (FDA) has approved the PharmaJet Stratis® 0.5mL Needle-Free Jet Injector for delivery of AFLURIA in individuals aged 18 to 64 years. This is the first needle-free delivery system approved by the FDA for the administration of an inactivated influenza vaccine. More.

08/05/2014
bioCSL Inc. Launches AFLURIA® Shipping Campaign for 2014-2015 Seasonal Influenza
bioCSL Inc. announced today it has commenced shipping its seasonal influenza vaccine AFLURIA® (Influenza Vaccine) for the 2014-2015 flu season. U.S. providers who ordered AFLURIA may be able to begin vaccinating as early as this month. More.

04/28/2014
bioCSL Supports Public Health Efforts in Laos with Donation of more than 700,000 Doses of Seasonal Influenza Vaccine
bioCSL, formerly CSL Biotherapies, has announced the donation of more than 700,000 doses of its influenza vaccine to the Partnership for Influenza Vaccine Introduction, an innovative program - spearheaded by the US Centers for Disease Control and Prevention (CDC) and the Task Force for Global Health (TFGH) - that helps low- and middle-income countries reduce annual morbidity and mortality from influenza. The program helps eligible countries create or expand public vaccination program infrastructures within their borders. This year marks the second consecutive year that bioCSL has donated vaccine to the program. More.

02/26/2014
CSL Biotherapies Inc. renamed bioCSL Inc.
CSL Biotherapies Inc. announced today it has changed its name to bioCSL Inc., effective February 21, 2014. This change is pursuant to the Australian, New Zealand and German renaming of the company, which occurred one year ago. More.

09/25/2013
CSL Biotherapies completes 2013-14 season AFLURIA® shipments
CSL Biotherapies Inc. announced today it has finalized shipment of 11 million doses of AFLURIA®, its seasonal influenza vaccine for the 2013-2014 season. Completion of the 2013-14 shipping campaign will ensure that healthcare providers using AFLURIA® are able to conduct their immunization programs as planned. More.

08/06/2013
CSL Biotherapies initiates shipments of its seasonal influenza vaccine to U.S. customers.

CSL Biotherapies Inc. announced today that shipment of its seasonal influenza vaccine for the 2013-2014 season has started.

More.

11/12/2009
CSL Biotherapies obtains FDA licensure for use of its thimerosal-free pandemic Influenza A (H1N1) 2009 Monovalent Vaccine in children
CSL Biotherapies, a subsidiary of CSL Limited (ASX: CSL), one of the world's leading manufacturers of influenza vaccine, announced that the U.S. Food and Drug Administration (FDA) has approved the company's application for accelerated approval of its seasonal flu vaccine, Afluria® (Influenza Virus Vaccine) for use in the pediatric population aged 6 months and older. More.

The information presented on this site is intended for US residents only.
© 2019 Seqirus All rights reserved.
Seqirus is a trademark of CSL Limited.

BCSL14-02-0003 06/2014